Your browser doesn't support javascript.
loading
Immunosuppressive niche engineering at the onset of human colorectal cancer.
Gatenbee, Chandler D; Baker, Ann-Marie; Schenck, Ryan O; Strobl, Maximilian; West, Jeffrey; Neves, Margarida P; Hasan, Sara Yakub; Lakatos, Eszter; Martinez, Pierre; Cross, William C H; Jansen, Marnix; Rodriguez-Justo, Manuel; Whelan, Christopher J; Sottoriva, Andrea; Leedham, Simon; Robertson-Tessi, Mark; Graham, Trevor A; Anderson, Alexander R A.
Afiliação
  • Gatenbee CD; Integrated Mathematical Oncology Department, H. Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, SRB 4, Tampa, FL, 336122, USA. chandler.gatenbee@moffitt.org.
  • Baker AM; Evolution and Cancer Laboratory, Centre for Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London, London, EC1M 6BQ, UK.
  • Schenck RO; Integrated Mathematical Oncology Department, H. Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, SRB 4, Tampa, FL, 336122, USA.
  • Strobl M; Wellcome Centre for Human Genetics, University of Oxford, Oxford, OX37BN, UK.
  • West J; Integrated Mathematical Oncology Department, H. Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, SRB 4, Tampa, FL, 336122, USA.
  • Neves MP; Integrated Mathematical Oncology Department, H. Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, SRB 4, Tampa, FL, 336122, USA.
  • Hasan SY; Evolution and Cancer Laboratory, Centre for Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London, London, EC1M 6BQ, UK.
  • Lakatos E; Evolution and Cancer Laboratory, Centre for Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London, London, EC1M 6BQ, UK.
  • Martinez P; Evolution and Cancer Laboratory, Centre for Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London, London, EC1M 6BQ, UK.
  • Cross WCH; Evolution and Cancer Laboratory, Centre for Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London, London, EC1M 6BQ, UK.
  • Jansen M; Lyon Cancer Institute, Lyon, France.
  • Rodriguez-Justo M; Evolution and Cancer Laboratory, Centre for Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London, London, EC1M 6BQ, UK.
  • Whelan CJ; Department of Pathology, University College London Hospital, London, UK.
  • Sottoriva A; Department of Pathology, University College London Hospital, London, UK.
  • Leedham S; Cancer Physiology, H. Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, SRB 4, Tampa, FL, 336122, USA.
  • Robertson-Tessi M; Department of Biological Sciences, University of Illinois at Chicago, 845 West Taylor Street, Chicago, IL, 60607, USA.
  • Graham TA; Center for Evolution and Cancer, Institute of Cancer Research, London, UK.
  • Anderson ARA; Wellcome Centre for Human Genetics, University of Oxford, Oxford, OX37BN, UK.
Nat Commun ; 13(1): 1798, 2022 04 04.
Article em En | MEDLINE | ID: mdl-35379804
ABSTRACT
The evolutionary dynamics of tumor initiation remain undetermined, and the interplay between neoplastic cells and the immune system is hypothesized to be critical in transformation. Colorectal cancer (CRC) presents a unique opportunity to study the transition to malignancy as pre-cancers (adenomas) and early-stage cancers are frequently resected. Here, we examine tumor-immune eco-evolutionary dynamics from pre-cancer to carcinoma using a computational model, ecological analysis of digital pathology data, and neoantigen prediction in 62 patient samples. Modeling predicted recruitment of immunosuppressive cells would be the most common driver of transformation. As predicted, ecological analysis reveals that progressed adenomas co-localized with immunosuppressive cells and cytokines, while benign adenomas co-localized with a mixed immune response. Carcinomas converge to a common immune "cold" ecology, relaxing selection against immunogenicity and high neoantigen burdens, with little evidence for PD-L1 overexpression driving tumor initiation. These findings suggest re-engineering the immunosuppressive niche may prove an effective immunotherapy in CRC.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma / Neoplasias Colorretais / Adenoma Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma / Neoplasias Colorretais / Adenoma Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article